Cargando…

Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study

PURPOSE: This nationwide retrospective study was conducted to evaluate the efficacy and safety of combined gemcitabine and docetaxel (GD) as an off-label therapy for advanced soft tissue sarcoma, which has limited treatment options owing to its rare occurrence. MATERIALS AND METHODS: A total of 228...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Yunjung, Yun, Mi Sun, Lim, Sang Hee, Lee, Jeeyun, Ahn, Jin-Hee, Kim, Yu Jung, Park, Kyong Hwa, Park, Young Suk, Lim, Ho Yeong, An, Hyonggin, Suh, Dong-Churl, Kim, Yeul Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784639/ https://www.ncbi.nlm.nih.gov/pubmed/28361521 http://dx.doi.org/10.4143/crt.2016.535

Ejemplares similares

Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis
por: Lee, Ha-young, et al.
Publicado: (2012)

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma
por: Dickson, Mark A., et al.
Publicado: (2015)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas
por: Attia, Steven, et al.
Publicado: (2023)

Caveolin-1 Modulates Docetaxel-Induced Cell Death in Breast Cancer Cell Subtypes through Different Mechanisms
por: Kang, Jinho, et al.
Publicado: (2016)

Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients
por: Tanaka, Kazuhiro, et al.
Publicado: (2016)

ERRATUM: Caveolin-1 Modulates Docetaxel-Induced Cell Death in Breast Cancer Cell Subtypes through Different Mechanisms
por: Kang, Jinho, et al.
Publicado: (2019)

Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study
por: Hara, Hitomi, et al.
Publicado: (2019)

Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma
por: Pan, Minggui, et al.
Publicado: (2021)

Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
por: Palmerini, E., et al.
Publicado: (2016)

Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
por: Pender, Alexandra, et al.
Publicado: (2018)

Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial
por: Kim, Seung Tae, et al.
Publicado: (2019)

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Gemcitabine Maintenance Therapy in Patients With Metastasized Soft Tissue Sarcomas
por: Harrer, Dennis Christoph, et al.
Publicado: (2021)

Response of follicular dendritic cell sarcoma to gemcitabine and docetaxel: report of two cases and literature review
por: Conry, Robert M
Publicado: (2014)

A Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel and Gemcitabine in Locally Advanced Breast Cancer
por: Jeon, Ye Won, et al.
Publicado: (2017)

Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis
por: Takahashi, Masanobu, et al.
Publicado: (2017)

A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas
por: Jones, Robin L., et al.
Publicado: (2019)

Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306
por: Tanaka, Kazuhiro, et al.
Publicado: (2022)

Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer
por: Gil, Eun Young, et al.
Publicado: (2017)

Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer
por: LIM, SUNG HEE, et al.
Publicado: (2023)

Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response
por: Hong, Jung Yong, et al.
Publicado: (2023)

A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma
por: Tansir, Ghazal, et al.
Publicado: (2023)

The pretreatment erythrocyte sedimentation rate predicts survival outcomes after surgery and adjuvant radiotherapy for extremity soft tissue sarcoma
por: Park, Geumju, et al.
Publicado: (2019)

Primary Alveolar Soft Part Sarcoma of the Lung
por: Kim, Yeong Dae, et al.
Publicado: (2007)

Docetaxel/gemcitabine: Various toxicities: 4 case reports
Publicado: (2021)

BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells
por: Kim, Hee Kyung, et al.
Publicado: (2016)

A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors
por: Yoon, Jong Hyung, et al.
Publicado: (2014)

The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer
por: Kim, Seung Tae, et al.
Publicado: (2018)

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
por: Seddon, Beatrice, et al.
Publicado: (2017)

Prognostic significance of WT1 expression in soft tissue sarcoma
por: Kim, Ahrong, et al.
Publicado: (2014)

Risk of Fall-Related Injuries Associated with Antidepressant Use in Elderly Patients: A Nationwide Matched Cohort Study
por: Jung, Yu-Seon, et al.
Publicado: (2022)

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

Metastatic follicular dendritic cell sarcoma treated with gemcitabine plus docetaxel with an outstanding survival: A case report and review of literature
por: Esmati, Ebrahim, et al.
Publicado: (2020)

A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS)
por: Kalofonos, Haralabos P., et al.
Publicado: (2004)

The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC)
por: Heo, Mi Hwa, et al.
Publicado: (2017)

Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment
por: Lee, Jung Hyun, et al.
Publicado: (2014)

Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series
por: Yoo, Kwai Han, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2bfgdfos5ktp07di2dgb8rk4ld